Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The mitotic spindle and potential development for targeting novel types of interactions

NCRI

Published: 6 Oct 2009

Views: 12745

Rating:

Save

Prof Ashok Venkitaraman, University of Cambridge, UK

Prof Venkitaraman discussing the mitotic spindle and potential development for targeting novel types of interactions for making new oncology drugs with Prof Gordon McVie at the NCRI cancer conference in Birmingham

GE Healthcare and HCA Hospitals had no involvement in the agenda or production of the interviews.

Categories:
Drug development

Related Videos

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising...

Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC ( Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium )

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial...

Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype ( Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows...

Dr Yan Zhang - Sichuan University, Chengdu, China

Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC ( Dr Yan Zhang - Sichuan University, Chengdu, China )

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

Using AI to identify patients at increased risk of side effects from radiation...

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

More from ecancer